From the March 2026 issue: #Guselkumab drives shifts in #Tcell populations in #psoriasis, and #transcriptomics may predict response https://ow.ly/FpxX50Xr8Wa #medderm #dermsky

Long-term Study Solidifies TREMFYA® as Leading Treatment for Psoriatic Arthritis New findings affirm TREMFYA® (guselkumab) as the leading IL-23 inhibitor in preventing joint damage in active psoriatic arthritis, with impressive long-term efficacy.

Long-term Study Solidifies TREMFYA® as Leading Treatment for Psoriatic Arthritis #United_States #New_York #TREMFYA® #guselkumab #Psoriatic_Arthritis

#Guselkumab drives shifts in #Tcell populations in #psoriasis, and #transcriptomics may predict response www.jidinnovations.org/article/S2667-0267(25)00... #medderm #dermsky

Farmaci: colite ulcerosa, risultati positivi a 48 settimane per guselkumab sottocute (Adnkronos) - In pazienti adulti con colite ulcerosa attiva da moderata a grave l'impiego di guselkumab somministrato per via sottocutanea come terapia di induzione e di mantenimento ha portato a remissione clinica ed endoscopica clinic...

Farmaci: colite ulcerosa, risultati positivi a 48 settimane per guselkumab sottocute ... LEGGI TUTTO #coliteulcerosa #guselkumab #salute #farmaci #terapia

TREMFYA®: A Breakthrough in Ulcerative Colitis Treatment with Sustained Results TREMFYA® (guselkumab) emerges as the first IL-23 inhibitor with a fully subcutaneous regimen, showing remarkable results in ulcerative colitis treatment over 48 weeks.

TREMFYA®: A Breakthrough in Ulcerative Colitis Treatment with Sustained Results #USA #Ulcerative_Colitis #TREMFYA® #Spring_House #guselkumab

Guselkumab Efficacious for Moderately to Severely Active Crohn Disease in Adults Subcutaneous guselkumab is safe and efficacious in adults with moderately to severely active Crohn disease.

#IV induction followed by subcutaneous maintenance therapy with #guselkumab is efficacious for adults with moderately to severely active #Crohn disease.

Read More: https://bit.ly/3HTzG9Y

Guselkumab prevents structural damage progression in psoriatic arthritis Guselkumab significantly improves symptoms and prevents structural joint damage progression versus placebo in people with psoriatic arthritis.

#MedNews - Guselkumab significantly improves symptoms and prevents structural joint damage progression versus placebo in people with #PsoriaticArthritis.

Full story 👉 buff.ly/QB84Uy2

#RheumSky #Guselkumab

TREMFYA® Gains FDA Approval for Subcutaneous Induction in Ulcerative Colitis Treatment Johnson & Johnson's TREMFYA® becomes the first and only fully subcutaneous IL-23 inhibitor, now approved for adult ulcerative colitis treatment.

TREMFYA® Gains FDA Approval for Subcutaneous Induction in Ulcerative Colitis Treatment #United_States #Ulcerative_Colitis #TREMFYA #Horsham #guselkumab

#biosimilars #PolpharmaBiologics #MSPharma #gastroenterology #neurology #dermatology #MENA #vedolizumab #ocrelizumab #guselkumab #ulcerativecolitis #Crohnsdisease #multiplesclerosis #plaquepsoriasis #psoriaticarthritis #biosimilarmanufacturing #MS #PolpharmaBiologicsGroup
zurl.co/GJnQQ

Me too: Guselkumab (TREMFYA) bei Colitis ulcerosa Ein weiterer Interleukin-23-Antikörper in der Therapie der moderaten bis schweren aktiven Colitis ulcerosa - was bringt er?

Me too: #Guselkumab (TREMFYA) bei #Colitis ulcerosa

Ein weiterer Interleukin-23-Antikörper in der Therapie der moderaten bis schweren aktiven Colitis ulcerosa - was bringt er?
www.arznei-telegramm.de/html/2025_07...

IL-23 Inhibitor Resolves Severe Psoriasis Triggered by Adalimumab A rare case of adalimumab-induced pustular psoriasis in a hidradenitis suppurativa patient was successfully treated with guselkumab, highlighting the value of IL-23 inhibitors in paradoxical reactions...

🚨 A patient with hidradenitis suppurativa developed severe pustular psoriasis from adalimumab. Guselkumab, an IL-23 inhibitor, resolved symptoms in 12 weeks with no recurrence after 1 year.
🔗 www.emjreviews.com/en-us/amj/de...
#Psoriasis #Hidradenitis #Guselkumab #AMJDermatology

Lo studio, inibitore Il-23 riduce segni e sintomi artrite psoriasica attiva (Adnkronos) - Sono stati presentati al Congresso europeo di reumatologia (Eular) 2025 di Barcellona, da Johnson & Johnson, i nuovi dati dello studio di fase 3b Apex che dimostrano l’efficacia a 24 settimane di guselkumab, anticorpo mo...

Lo studio, inibitore Il-23 riduce segni e sintomi artrite psoriasica attiva ... LEGGI TUTTO #artritepsoriasica #guselkumab #salute #reumatologia #EULAR2025

Johnson & Johnson's TREMFYA® Demonstrates Efficacy in Psoriatic Arthritis Treatment Discover how Johnson & Johnson's TREMFYA® offers significant benefits in treating active psoriatic arthritis, showcasing remarkable results in the APEX study.

Johnson & Johnson's TREMFYA® Demonstrates Efficacy in Psoriatic Arthritis Treatment #United_States #New_Brunswick #TREMFYA #guselkumab #Psoriatic_Arthritis

MHRA approves guselkumab for Crohn’s disease and ulcerative colitis - PharmaTimes Regulator confirms safety and efficacy of new treatment option for patient

#gastroenterology #MHRA #guselkumab #Tremfya #jmj #janssen #Crohnsdisease #ulcerativecolitis #plaquepsoriasis #psoriaticarthritis #activeCrohnsdisease #Clinicalstudies #Crohnsdiseasepatients #guselkumabtreatment
pharmatimes.com/news/mhra-ap...

New Findings Position TREMFYA® as First IL-23 Inhibitor for Ulcerative Colitis Treatment Johnson & Johnson unveils data positioning TREMFYA® as the pioneering IL-23 inhibitor for ulcerative colitis with subcutaneous induction, demonstrating promising efficacy.

New Findings Position TREMFYA® as First IL-23 Inhibitor for Ulcerative Colitis Treatment #United_States #San_Diego #Ulcerative_Colitis #TREMFYA® #guselkumab

Johnson & Johnson shares positive late-stage results for Tremfya in psoriatic arthritis - PMLiVE The inflammatory condition affects approximately 30% of psoriasis patients

#immunology #rheumatology #InnovativeMedicine #jointhealth #JohnsonandJohnson #JandJ #JnJ #Tremfya #guselkumab #psoriaticarthritis #PsA #APEXtrial #activePsA #IL23blocker #pathogenesis #inflammatorydiseases #CD64receptor #CD64receptorbinder #IL23inhibitor #IL23treatment
pmlive.com/pharma_news/...

FDA Approves TREMFYA® for Treating Crohn's Disease with Flexible Induction Options TREMFYA® has received FDA approval as the first dual-action IL-23 inhibitor for adults with Crohn's disease, offering both subcutaneous and intravenous treatment options.

FDA Approves TREMFYA® for Treating Crohn's Disease with Flexible Induction Options #United_States #Crohn's_Disease #TREMFYA #Horsham #guselkumab

TREMFYA® Shows Promise as a New Ulcerative Colitis Treatment with Unique Induction Options Johnson & Johnson's latest data on TREMFYA® reveals potential dual induction treatment methods for ulcerative colitis patients, enhancing therapeutic options.

TREMFYA® Shows Promise as a New Ulcerative Colitis Treatment with Unique Induction Options #USA #Ulcerative_Colitis #Spring_House #TREMFYA #guselkumab